← Back to all signals
RESEARCH PAPER ANALYSIS

Cross-sectional comparison of lower-limb muscle strength and contractile properties according to Parkinson's disease and sarcopenia status.

In a cross-sectional cohort of 60 older adults, Parkinson's disease was associated with prolonged contraction time and reduced maximal muscle displacement in the lateral gastrocnemius (TMG), whereas sarcopenic participants had substantially lower hip and knee extension isometric strength.

PMID41939735
JournalFrontiers in medicine
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

In a cross-sectional cohort of 60 older adults, Parkinson's disease was associated with prolonged contraction time and reduced maximal muscle displacement in the lateral gastrocnemius (TMG), whereas sarcopenic participants had substantially lower hip and knee extension isometric strength.

WHY IT MATTERS

Research significance

The paper highlights distinct, measurable peripheral muscle phenotypes in PD versus sarcopenia that could inform functional biomarkers and guide targeted rehabilitation or monitoring, but it provides limited mechanistic or drug-target insights for therapeutic discovery.

ABSTRACT

Source abstract

This cross-sectional study compares lower-limb isometric strength and tensiomyography-derived contractile properties between patients with Parkinson's disease and age-matched controls across sarcopenia classifications, with predefined covariate control. However, despite the clinical relevance of muscle dysfunction in Parkinson's disease and sarcopenia, TMG-derived assessments of muscle contractile properties remain limited in these populations. PD is a progressive neurodegenerative disorder marked by motor symptoms such as bradykinesia and rigidity, while sarcopenia is an age-related condition characterized by loss of muscle mass and strength. Both contribute to impaired mobility and increased fall risk, though their physiological signatures may differ. In this cross-sectional study, 60 older adults aged 58-85 years (20 with PD and 40 age-matched healthy controls; 39 males, 21 females) were assessed for isometric muscle strength across eight major lower limb movements using a handheld dynamometer, and for muscle contractile properties of four muscles-lateral gastrocnemius, medial gastrocnemius, soleus, and tibialis anterior-using tensiomyography (TMG). Compared to healthy controls, individuals with PD showed prolonged contraction time (Tc, the time between 10 and 90% of maximal contraction) and reduced maximal muscle displacement (Dm, the peak radial displacement of the muscle belly) in the lateral gastrocnemius (e.g., Tc↑: + 23.6%, Dm↓: -17.8%), suggesting neuromuscular impairment. Sarcopenic participants exhibited lower peak isometric strength in hip and knee extension tasks (e.g., -29.5% in hip extension, -26.2% in knee extension based on maximal voluntary contraction), reflecting task-specific deficits likely related to proximal muscle mass loss. While these results are based on cross-sectional data and should be interpreted cautiously, they suggest the presence of differing neuromuscular patterns in PD and sarcopenia. The findings offer preliminary insights into how PD and sarcopenia may differentially affect muscle strength and contractile characteristics, which could inform future research and clinical considerations regarding lower limb function.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic